Clinical Trial Update: Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial of 1612 capsules for amnestic mild cognitive impairment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• 1612 capsules

Snippet

Sponsor: Dongzhimen Hospital, Beijing | Conditions: Mild Cognitive Impairment | Phase 4 | Status: WITHDRAWN